Advarra, the provider of institutional review board (IRB), institutional biosafety committee (IBC), research quality and compliance consulting services, and standards-based research technology solutions, announces Advarra GPS-a completely managed service to guide, protect, and streamline research programs for health systems, hospitals, and academic medical centers. Advarra GPS helps institutions navigate the challenges of operating a local IRB office and chart a path to increased efficiency, greater compliance, and overall scalability.
“We continue to offer our institutional partners new services to guide and improve their research programs. Advarra GPS is truly an innovation that demonstrates our commitment to supporting research institutions as they navigate an increasingly complex and challenging landscape,” said Pat Donnelly, CEO of Advarra. “Our commitment to research compliance services for institutions is unwavering. From our recent acquisition of the industry’s leading CTMS, OnCore by Forte, to the launch of Advarra GPS and many innovations to come, the future of research powered by Advarra is exciting. ”
Advarra offers the institutional reach of any independent IRB, serving well over 3,200 research institutions, health systems, and academic medical centers.
“Navigating research regulations and maintaining a local IRB office is complex and costly. Research institutions often seek increased capacity,” said James Riddle, Vice President of Institutional Services at Advarra. “Advarra GPS charts a course to success by providing a roadmap to guide these organizations through compliance risks, protect from staffing challenges, and streamline approval times.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.